Share

EUPATI project will provide cancer patients’ with scientifically reliable, objective and comprehensive information

The European Patients’ Academy on Therapeutic Innovation (EUPATI) project is a consortium of 29 organizations led by the European Patients’ Forum and including the EORTC among others. EUPATI aims to provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical research and development and increase the capacity of well-informed patients to be effective advocates and advisors, for example in clinical trials, with regulatory authorities and in ethics committees.

Development of medicines is a complicated process. It is highly regulated, expensive, and generally misunderstood by the general public. EUPATI plans to address these issues and improve the availability of information for patients. For example, EUPATI plan to develop and distribute user-friendly educational modules concerning therapeutic innovations, build upon the competencies of well informed patients and the public about pharmaceutical research and development, and facilitate patient involvement in all facets of drug development.

The first public meeting of the European Patients’ Academy on Therapeutic Innovation will be held during the Drug Information Association EuroMeeting on 27 March 2012 from 14:00-16:00 in Copenhagen.

http://www.patientsacademy.eu/index.php/en/news/13-eupati-launch-cp

You can learn more about EUPATI on their website, or follow them online:

www.patientsacademy.eu

www.facebook.com/patientsacademy.eu

Twitter: @eupatients

Back to news list

Related News

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff